Amendment H-1166 to SF 326
Relating to the ordering and administering of epinephrine auto-injectors and self-administered hormonal contraceptives to persons ages eighteen years and older by a pharmacist pursuant to statewide protocols
Never voted on
Filed March 29, 2023 in the House by the House Health Committee
What it changes
- Page 1, by striking lines 24 through 32 and inserting: “Sec. ___. Section 155A.46, Code 2023, is amended by adding the following new subsection: NEW SUBSECTION .
- A pharmacist may, pursuant to statewide protocols developed by the board in consultation with the department of health and human services, order and dispense to patients eighteen years and older self-administered hormonal contraceptives. For the purpose of this subsection, “self-administered hormonal contraceptive” means a self-administered hormonal contraceptive that is approved by the United States food and drug administration to prevent pregnancy. “Self-administered hormonal contraceptive” includes an oral hormonal contraceptive, a hormonal vaginal ring, and a hormonal contraceptive patch, but does not include any drug intended to induce an abortion as defined in section 146.1. a. In ordering and dispensing a self-administered hormonal contraceptive to a patient under this subsection, a pharmacist shall comply with all of the following: (1) For an initial dispensing of a self-administered hormonal contraceptive, the pharmacist may dispense only up to a three-month supply at one time of the self-administered hormonal contraceptive. (2) For any subsequent dispensing of the same self-administered hormonal contraceptive, the pharmacist may dispense up to a twelve-month supply at one time of the self-administered hormonal contraceptive. b. The statewide protocols shall require a pharmacist who dispenses a self-administered hormonal contraceptive under this subsection to do all of the following: (1) Retain a record of each patient to whom a self-administered hormonal contraceptive is dispensed under this subsection and submit the record to the department of health and human services. (2) Complete a standardized training program and continuing education requirements approved by the board in consultation with the board of medicine and the department of health and human services that are related to ordering and dispensing a self-administered hormonal contraceptive and include education regarding all contraceptive methods approved by the United States food and drug administration. (3) Obtain a completed self-screening risk assessment, approved by the department of health and human services in collaboration with the board and the board of medicine, from each patient, verify the identity and age of each patient, and perform a blood pressure screening on each patient prior to dispensing the self-administered hormonal contraceptive to the patient. (4) Provide the patient with all of the following: (a) Written information regarding all of the following: (i) The importance of completing an appointment with the patient’s primary care or women’s health care practitioner to obtain preventative care, including but not limited to recommended tests and screenings. (ii) The effectiveness and availability of long-acting reversible contraceptives as an alternative to self-administered hormonal contraceptives. (b) A copy of the record of the pharmacist’s encounter with the patient that includes all of the following: (i) The patient’s completed self-screening risk assessment. (ii) A description of the self-administered hormonal contraceptive dispensed, or the basis for not dispensing a self-administered hormonal contraceptive. (c) Patient counseling regarding all of the following: (i) The appropriate administration and storage of the self-administered hormonal contraceptive. (ii) Potential side effects and risks of the self-administered hormonal contraceptive. (iii) The need for backup contraception. (iv) When to seek emergency medical attention. (v) The risk of contracting a sexually transmitted infection or disease, and ways to reduce such a risk. c. The statewide protocols shall prohibit a pharmacist who orders and dispenses a self-administered hormonal contraceptive under this subsection from doing any of the following: (1) Requiring any other prescription drug order authorized by a practitioner prior to dispensing the self-administered hormonal contraceptive to a patient. (2) Requiring a patient to schedule an appointment with the pharmacist for the ordering or dispensing of a self-administered hormonal contraceptive. (3) Dispensing a self-administered hormonal contraceptive to a patient for more than fifteen months after the date a self-administered hormonal contraceptive is initially dispensed to the patient, if the patient has not consulted with a primary care or women’s health care practitioner during the preceding fifteen months, in which case the pharmacist shall refer the patient to a primary care or women’s health care practitioner. (4) Dispensing a self-administered hormonal contraceptive to a patient if the results of the self-screening risk assessment indicate it is unsafe for the pharmacist to dispense the self-administered hormonal contraceptive to the patient, in which case the pharmacist shall refer the patient to a primary care or women’s health care practitioner. d. A pharmacist who orders and dispenses a self-administered hormonal contraceptive shall be immune from criminal and civil liability arising from any damages caused by the ordering, dispensing, administering, or use of a self-administered hormonal contraceptive. Sec. ___. INFORMATION PROGRAM FOR DRUG PRESCRIBING AND DISPENSING —— SELF-ADMINISTERED HORMONAL CONTRACEPTIVES. The board of pharmacy in collaboration with the board of medicine and the department of health and human services shall expand the information program for drug prescribing and dispensing established pursuant to section 124.551, to collect from pharmacists information relating to the dispensing of self-administered hormonal contraceptives as provided pursuant to section 155A.46. The board of pharmacy shall adopt rules pursuant to chapter 17A related to registration of participating pharmacists, the information to be reported by a pharmacist to the information program, access to information from the program, and other rules necessary to carry out the purposes and to enforce the provisions of this section.”
- Title page, line 1, by striking “and administering” and inserting “, administering, and dispensing”